# c-Cbl(Phospho-Tyr700)
# Antibody

**#11549**

**Catalog Number:** 11549-1, 11549-2

**Amount:** 50μg/50μl, 100μg/100μl

**Swiss-Prot No. :** P22681

**Form of Antibody:** Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl,0.02% sodium azide and 50% glycerol.

**Storage/Stability:** Store at -20℃/1 year

**Immunogen:** The antiserum was produced against synthesized phosphopeptide derived from human c-Cbl around the phosphorylation site of threonine700 (T-E-Y$_P$-M-T)

**Purification:** The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.

**Specificity/Sensitivity:** c-Cbl(phospho-Tyr700) antibody detects endogenous levels of c-Cbl only when phosphorylated at tyrosine 700

**Reactivity:**   Human

**Applications:**

Predicted MW: 120kd

IHC: 1:50~100 IF:1:100~1:200

P-Peptide      -                    +

Immunohistochemical analysis of paraffin-embedded

  human breast carcinoma tissue, using c-Cbl (phospho-Tyr700) Antibody (#11549).



Immunofluorescence staining of methanol-fixed HeLa cells using c-Cbl (phospho-Tyr700)
Antibody (#11549, Red).

## Background :

Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative
regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3
ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then
transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor
tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.

## References：

 Blake, T.J. et al. (1991) *Oncogene* 6, 653-657.
Thien, C.B. and Langdon, W.Y. (1998) *Immunol. Cell Biol.* 76, 473-482.
Kamei, T. et al. (2000) *Int. J. Oncol.* 17, 335-339.
Hunter, C. et al. (1999) *J. Biol. Chem.* 274, 2097-2106